Financial & competing interests disclosure
The authors are inventors on a patent application covering peptide Allo-aca and analogs for the treatment of various cancer, arthritis and autoimmune disease forms. The patent is owned by Temple University and currently not licensed to any entity, although Peptherx, Inc., a biotechnology company founded by the authors, has a temporary option for the technology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.